# Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Canonical URL: https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-ceo-transition-as-company-advances-strategy-to-extend-orexin-leadership-into-multiple-neuroscience-indications
Ticker: CNTA
Company: Centessa Pharmaceuticals
Source: Centessa Pharmaceuticals
Published: 2025-12-11 12:00 EST
Original Source URL: https://investors.centessa.com
## Summary

Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today

## Article Body
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today
## Recent Company News
- 2026-03-31 10:45 EST — [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders](https://biopharmsignal.com/news/CNTA/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders) — Source: Centessa Pharmaceuticals
- 2026-02-03 13:00 EST — [Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Centessa Pharmaceuticals
- 2026-01-14 22:00 EST — [Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-poster-presentation-of-new-preclinical-data-supporting-expansion-of-orexin-receptor-2-ox2r-agonist-pipeline-into-neuropsychiatric-indications-at-the-64th-acnp-annual-meeting) — Source: Centessa Pharmaceuticals
- 2025-12-11 12:00 EST — [Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-ceo-transition-as-company-advances-strategy-to-extend-orexin-leadership-into-multiple-neuroscience-indications) — Source: Centessa Pharmaceuticals
- 2025-11-12 01:40 EST — [Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-pricing-of-250-000-000-public-offering-of-american-depositary-shares) — Source: Centessa Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)